Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

The pyrazinamide susceptibility breakpoint above which combination therapy fails

(2014) T. Gumbo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

The Evaluation of Multivariate Adaptive Regression Splines for the Prediction of Antitumor Activity of Acridinone Derivatives

(2013) Marcin Koba et al.   Medicinal Chemistry

A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

(2012) E. Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

(2011) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients

(2011) Siv Jönsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling

(2011) Shashikant Srivastava et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients

(2011) Justin J. Wilkins et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial

(2010) Marianne E Visser et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

(2010) T. Gumbo   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania

(2010) Mbazi Senkoro et al.   BMC INFECTIOUS DISEASES

Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity

(2010) Geraint R. Davies   TUBERCULOSIS

Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis

(2009) D. Almeida et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

(2009) T. Gumbo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

(2009) Sekai Chideya et al.   CLINICAL INFECTIOUS DISEASES

Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis by Use of MGIT 960 and EpiCenter Instrumentation

(2009) B. Springer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP–SNP interactions and their application in prostate cancer

(2008) Hui-Yi Lin et al.   JOURNAL OF HUMAN GENETICS